To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Clinical trial NCT05356741 · RECRUITING
Trial details
- NCT number
- NCT05356741
- Sponsor
- Vir Biotechnology, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-13
- Primary completion
- 2028-04-01
- Enrollment
- 645
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.